Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

CANCER IMMUNOLOGY

Immuno-epigenetic escape of cancer stem cells

Nature Immunology volume 23, pages 1300–1302 (2022)Cite this article

Subjects

The net effect of type I interferon (IFN-I) signaling on tumor control depends on various factors, including the potential engagement of adaptive anticancer immunity. New findings delineate a targetable epigenetic mechanism by which suboptimal IFN-I signaling promotes tumor progression in the context of cancer stem cell expansion and immunoevasion.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Suboptimal ICD induction coupled to CSC expansion by IFN-I-driven KDM1B activation.

References

  1. McNab, F., Mayer-Barber, K., Sher, A., Wack, A. & O’Garra, A. Nat. Rev. Immunol. 15, 87–103 (2015).

    Article  CAS  Google Scholar 

  2. Kroemer, G., Galassi, C., Zitvogel, L. & Galluzzi, L. Nat. Immunol. 23, 487–500 (2022).

    Article  CAS  Google Scholar 

  3. Musella, M. et al. Nat. Immunol. https://doi.org/10.1038/s41590-022-01290-3 (2022).

    Article  PubMed  Google Scholar 

  4. Sistigu, A. et al. Nat. Med. 20, 1301–1309 (2014).

    Article  CAS  Google Scholar 

  5. Yamazaki, T. et al. Nat. Immunol. 21, 1160–1171 (2020).

    Article  CAS  Google Scholar 

  6. Rodriguez-Ruiz, M. E. et al. Oncoimmunology 8, e1655964 (2019).

    Article  Google Scholar 

  7. Weichselbaum, R. R. et al. Proc. Natl Acad. Sci. USA 105, 18490–18495 (2008).

    Article  CAS  Google Scholar 

  8. Palucka, A. K. & Coussens, L. M. Cell 164, 1233–1247 (2016).

    Article  CAS  Google Scholar 

  9. Vanpouille-Box, C., Demaria, S., Formenti, S. C. & Galluzzi, L. Cancer Cell 34, 361–378 (2018).

    Article  CAS  Google Scholar 

  10. Hopfner, K. P. & Hornung, V. Nat. Rev. Mol. Cell Biol. 21, 501–521 (2020).

    Article  CAS  Google Scholar 

  11. Rehwinkel, J. & Gack, M. U. Nat. Rev. Immunol. 20, 537–551 (2020).

    Article  CAS  Google Scholar 

  12. Bayik, D. & Lathia, J. D. Nat. Rev. Cancer 21, 526–536 (2021).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Radiation Oncology, Weill Cornell Medical College, New York, NY, USA

    Lorenzo Galluzzi

  2. Sandra and Edward Meyer Cancer Center, New York, NY, USA

    Lorenzo Galluzzi

  3. Caryl and Israel Englander Institute for Precision Medicine, New York, NY, USA

    Lorenzo Galluzzi

  4. Centre de Recherche des Cordeliers, Equipe labellisée par la Ligue contre le cancer, Université de Paris Cité, Sorbonne Université, Inserm U1138, Institut Universitaire de France, Paris, France

    Guido Kroemer

  5. Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Center, Université Paris Saclay, Villejuif, France

    Guido Kroemer

  6. Institut du Cancer Paris CARPEM, Department of Biology, APHP, Hôpital Européen Georges Pompidou, Paris, France

    Guido Kroemer

Authors
  1. Lorenzo Galluzzi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Guido Kroemer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Lorenzo Galluzzi or Guido Kroemer.

Ethics declarations

Competing interests

L.G. declares having held research contracts with Lytix Biopharma and Promontory, has received consulting/advisory honoraria from Boehringer Ingelheim, AstraZeneca, OmniSEQ, Onxeo, The Longevity Labs, Inzen, Sotio, Promontory, Noxopharm, EduCom, and the Luke Heller TECPR2 Foundation, and holds Promontory stock options. G.K. declares having held research contracts with Daiichi Sankyo, Eleor, Kaleido, Lytix Pharma, PharmaMar, Osasuna Therapeutics, Samsara Therapeutics, Sanofi, Sotio, Tollys, Vascage and Vasculox/Tioma, has received consulting/advisory honoraria from Reithera, is on the Board of Directors of the Bristol Myers Squibb Foundation France, is a scientific co-founder of everImmune, Osasuna Therapeutics, Samsara Therapeutics and Therafast Bio, and is the inventor of patents covering therapeutic targeting of aging, cancer, cystic fibrosis and metabolic disorders, including patents licensed to Bayer (WO2014020041-A1, WO2014020043-A1), Bristol-Myers Squibb (WO2008057863-A1), Osasuna Therapeutics (WO2019057742A1), PharmaMar (WO2022048775-A1), Raptor Pharmaceuticals (EP2664326-A1), Samsara Therapeutics (GB202017553D0 and GB202017030D0), and Therafast Bio (EP3684471A1).

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Galluzzi, L., Kroemer, G. Immuno-epigenetic escape of cancer stem cells. Nat Immunol 23, 1300–1302 (2022). https://doi.org/10.1038/s41590-022-01293-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41590-022-01293-0

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer